Author

Alejandra Ramos

Instituto de Salud Carlos III

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Alberto MartíniD· 1 shared Ana Montero‐CalleiD· 1 shared Borja Vilaplana‐MartíiD· 1 shared Carolina EpifanoiD· 1 shared Déborah Gómez-Domínguez· 1 shared Diego Megı́asiD· 1 shared Ignacío Pérez de CastroiD· 1 shared Isabel CuestaiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alberto MartínORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti-tumoral compounds

Sandra Amarilla‐Quintana, Paloma Navarro, Iván Hernández, Alejandra Ramos, Ana Montero‐Calle, Pablo Cabezas‐Sainz, María J. Barrero, Diego Megı́as, Borja Vilaplana‐Martí, Carolina Epifano, Déborah Gómez-Domínguez, Sara Monzón, Isabel Cuesta, Laura E. Sanchez, Rodrigo Barderas, , Ignacío Pérez de Castro

This study uses CRISPR to eliminate the FOXL2 c.402C>G mutation in granulosa tumor cells, reducing malignancy and identifying anti-tumoral compounds.

Molecular Oncology · Jan 8, 2025Peer-reviewedCancer Biology